Clinical trial NCT00041288 (phase 2, status: terminated)
Conditions: leukemia, lymphoma
ICD codes: C95.91, C95.92, Z80.6, Z85.6, C90.11, C90.12, C91.01, S33.110S, S33.111S, S33.120S, S33.121S, S33.130S, S33.131S, S33.140S
Drugs: cyclophosphamide, cyclosporine, fludarabine phosphate, methotrexate, mycophenolate mofetil, tacrolimus
SMILES: ClCCN(CCCl)P1(=O)NCCCO1, CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O)C(C)C, NC1=NC(F)=NC2=C1N=CN2[C@@H]1O[C@H](CO)[C@@H](O)[C@@H]1O, CN(CC1=CN=C2N=C(N)N=C(N)C2=N1)C1=CC=C(C=C1)C(=O)N[C@@H](CCC(O)=O)C(O)=O, N[C@@H](CCCNC(N)=N)C(O)=O, COC1=CC2=C(C(OC)=C1OC)C1=CC=C(OC)C(=O)C=C1C(CC2)NC(C)=O
Reason stopped: 
    poor accrual and difficulty with multicenter logistics
  
Eligibility criteria:

        DISEASE CHARACTERISTICS:

          -  Diagnosis of chronic lymphocytic leukemia or

          -  Diagnosis of non-Hodgkin's lymphoma

          -  Lymphoplasmacytic lymphoma

          -  Grade I follicular small cleaved cell lymphoma

          -  Grade II follicular mixed cell lymphoma

          -  Diffuse small cleaved cell lymphoma

          -  Small lymphocytic lymphoma

          -  Relapsed after at least 1 course of prior therapy

          -  Availability of a 6/6 human leukocyte antigen (HLA) A, B, and DR identical sibling
             donor

          -  Nonmyeloablative transplantation candidate

          -  No clinically significant effusions or ascites that would preclude administration of
             methotrexate

        PATIENT CHARACTERISTICS:

        -Age: 18 to 75

        Performance status:

          -  Eastern Cooperative Oncology Group (ECOG) 0-2 OR Zubrod 0-2

          -  Life expectancy: At least 6 months

          -  Hematopoietic: Not specified

          -  Hepatic: Bilirubin no greater than 3 mg/dL

          -  Renal: Creatinine no greater than 2 mg/dL

          -  Cardiovascular: left ventricular ejection fraction (LVEF) at least 40% on multigated
             acquisition (MUGA) scan or echocardiogram

          -  Pulmonary: diffusing capacity of lung for carbon monoxide (DLCO) at least 50% of
             predicted

        OTHER:

          -  Not pregnant or nursing

          -  Negative pregnancy test

          -  Fertile patients must use effective contraception

          -  No uncontrolled bacterial, viral, fungal, or parasitic infection

          -  Human Immunodeficiency Virus (HIV)1 and Human Immunodeficiency Virus (HIV)2 negative

          -  No other active malignancy except basal cell skin cancer

          -  No recent history of drug or alcohol abuse

          -  No other primary disease or comorbid illness that would severely limit life expectancy

        PRIOR CONCURRENT THERAPY

          -  Biologic therapy:See Disease Characteristics

          -  Biologic therapy:Prior autologous bone marrow transplantation allowed if disease has
             progressed after transplantation

          -  Biologic therapy:No entry on study as part of a tandem autologous transplantation
             followed by nonmyeloablative allograft protocol

          -  Chemotherapy: Not specified

          -  Endocrine therapy: Not specified

          -  Radiotherapy:Not specified

          -  Surgery: Not specified